De Keyser Filip, Van den Bosch Filip, Mielants Herman
Department of Rheumatology, Gent University Hospital, De Pintelaan 185, B-9000 Gent, Belgium.
Cytokine. 2006 Mar 7;33(5):294-8. doi: 10.1016/j.cyto.2006.01.004. Epub 2006 Mar 3.
Ankylosing spondylitis (AS) is the prototype disease within the spondyloarthropathies (SpA), a group of diseases presenting mainly with spondylitis, pauci-articular peripheral arthritis and enthesiopathy. Non-steroidal anti-inflammatory drugs (NSAID) are the classical cornerstone of medical therapy in these patients; no real disease modifying antirheumatic treatment was available, until recently. TNF-alpha blocking agents (monoclonal antibodies or soluble receptors) are the first representative drugs, of which the indication has recently been expanded to encompass also patients with AS. Here, we review the data on clinical efficacy and safety, with focus on the compounds infliximab and etanercept. Publication of trial results with adalimumab is still under way; the efficacy of this compound in AS seems comparable with the other two agents.
强直性脊柱炎（AS）是脊柱关节炎（SpA）中的典型疾病，这是一组主要表现为脊柱炎、少关节外周关节炎和附着点病的疾病。非甾体抗炎药（NSAID）是这些患者药物治疗的经典基石；直到最近，还没有真正的改善病情抗风湿治疗方法。肿瘤坏死因子-α阻断剂（单克隆抗体或可溶性受体）是首批代表性药物，其适应证最近已扩大到包括AS患者。在此，我们回顾关于临床疗效和安全性的数据，重点关注英夫利昔单抗和依那西普这两种药物。阿达木单抗的试验结果仍在发表过程中；该药物在AS中的疗效似乎与其他两种药物相当。
